Prediction of outcome by early response in childhood acute lymphoblastic leukemia

Klinische Padiatrie

Volumn 225, Issue SUPPL1, 2013, Pages

  Moricke A ^a   Lauten, M ^b   Beier, R ^c   Odenwald, E ^c   Stanulla, M ^a   Zimmermann, M ^c   Attarbaschi, A ^d   Niggli, F ^e   Schrappe, M ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

childhood acute lymphoblastic leukemia; clinical trial; early treatment response

Indexed keywords

METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CANCER PATIENT; CANCER PROGNOSIS; CELL LINEAGE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRE B LYMPHOCYTE; PREDICTION; PREDICTIVE VALUE; SCHOOL CHILD; SINGLE DRUG DOSE; T CELL LEUKEMIA; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BIOPSY; BONE MARROW; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; PATIENT OUTCOME ASSESSMENT; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK ASSESSMENT; VINCRISTINE;

EID: 84878035220     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1337964     Document Type: Article

References (38)

1. Arico M., Basso G., Mandelli F. et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer: 1995; 75 1684 1693
2. Bowman W. P., Larsen E. L., Devidas M. et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer: 2011; 57 569 577
3. Chessells J. M., Bailey C., Richards S. M. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet: 1995; 345 143 148
4. Conter V., Bartram C. R., Valsecchi M. G. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood: 2010; 115 3206 3214
5. Dordelmann M., Reiter A., Borkhardt A. et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood: 1999; 94 1209 1217 (Pubitemid 29380401)
6. Felice M. S., Zubizarreta P. A., Alfaro E. M. et al. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol: 2001; 23 411 415 (Pubitemid 33031767)
7. Fronkova E., Mejstrikova E., Avigad S. et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia: 2008; 22 989 997 (Pubitemid 351689881)
8. Gajjar A., Ribeiro R., Hancock M. L. et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood: 1995; 86 1292 1295
9. Gaynon P. S. Prognostic factors in acute lymphoblastic leukemia. J Pediatr Hematol Oncol: 2000; 22 403 404
10. Gaynon P. S., Angiolillo A. L., Carroll W. L. et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia: 2010; 24 285 297
11. Gaynon P. S., Bleyer W. A., Steinherz P. G. et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol: 1990; 18 273 279 (Pubitemid 20219917)
12. Gaynon P. S., Desai A. A., Bostrom B. C. et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer: 1997; 80 1717 1726 (Pubitemid 27475928)
13. Gaynon P. S., Trigg M. E., Heerema N. A. et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia: 2000; 14 2223 2233 (Pubitemid 32042263)
14. Haw R., Sawka C. A., Franssen E. et al. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol: 1994; 12 1074 1084 (Pubitemid 24145339)
15. Keating M. J., Smith T. L., Gehan E. A. et al. Factors related to length of complete remission in adult acute leukemia. Cancer: 1980; 45 2017 2029 (Pubitemid 10150414)
16. Lange B. J., Bostrom B. C., Cherlow J. M. et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood: 2002; 99 825 833 (Pubitemid 34525542)
17. Lauten M., Moricke A., Beier R. et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica: 2012; 97 1048 1056
18. Lauten M., Stanulla M., Zimmermann M. et al. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr: 2001; 213 169 174 (Pubitemid 32801568)
19. Matloub Y., Bostrom B. C., Hunger S. P. et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood: 2011; 118 243 251
20. Matloub Y., Lindemulder S., Gaynon P. S. et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood: 2006; 108 1165 1173 (Pubitemid 44232011)
21. Miller D. R., Leikin S., Albo V. et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from childrens cancer study group. Cancer: 1983; 51 1041 1049
22. Miller D. R., Leikin S., Albo V. et al. Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report. Cancer Treat Rep: 1980; 64 381 392
23. Möricke A., Reiter A., Zimmermann M. et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood: 2008; 111 4477 4489
24. Möricke A., Zimmermann M., Reiter A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia: 2010; 24 265 284
25. Nachman J., Sather H. N., Gaynon P. S. et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol: 1997; 15 2222 2230 (Pubitemid 27251122)
26. Oudot C., Auclerc M. F., Levy V. et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol: 2008; 26 1496 1503
27. Reiter A., Schrappe M., Ludwig W. D. et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood: 1994; 84 3122 3133 (Pubitemid 24328106)
28. Riehm H., Reiter A., Schrappe M. et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr: 1987; 199 151 160 (Pubitemid 17079852)
29. Sandlund J. T., Harrison P. L., Rivera G. et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood: 2002; 100 43 47 (Pubitemid 35177426)
30. Schrappe M., Reiter A., Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol: 1996; 14 2403 2406 (Pubitemid 26264895)
31. Schrappe M., Valsecchi M. G., Bartram C. R. et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood: 2011; 118 2077 2084
32. Schultz K. R., Pullen D. J., Sather H. N. et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood: 2007; 109 926 935 (Pubitemid 46220635)
33. Seibel N. L., Steinherz P. G., Sather H. N. et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood: 2008; 111 2548 2555
34. Smith M., Arthur D., Camitta B. et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol: 1996; 14 18 24 (Pubitemid 26019992)
35. Smith M., Bleyer A., Crist W. et al. Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol: 1996; 14 680 681 (Pubitemid 26051038)
36. Steinherz P. G., Gaynon P. S., Breneman J. C. et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol: 1996; 14 389 398 (Pubitemid 26050999)
37. Thyss A., Suciu S., Bertrand Y. et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukaemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. J Clin Oncol: 1997; 15 1824 1830 (Pubitemid 27209510)
38. Vora A., Mitchell C. D., Lennard L. et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet: 2006; 368 1339 1348 (Pubitemid 44528747)